TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multi-center, Open-label Study to Determine Long-term Safety, Tolerability and Efficacy of Split-dose Oral Regimens of Tolvaptan Tablets in a Range of 30 to 120 mg/d in Patients With Autosomal Dominant Polycystic Kidney Disease
Brief Summary: This study's purpose is to evaluate the long-term safety of open-label tolvaptan regimens to determine the maximally-tolerated dose and acquire pilot efficacy data in patients with autosomal dominant polycystic kidney disease (ADPKD).


Options:
A: Arm Label: Sirolimus; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): Sirolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Tolvaptan 45/15 mg/day orally for up to 4 years; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Tolvaptan 60/30 mg/day orally for up to 4 years; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan 45/15 mg/day orally for up to 4 years, Tolvaptan 60/30 mg/day orally for up to 4 years
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Standard; Assigned to Arm(s): 1
D: Arm Label: somatostatin; Type: EXPERIMENTAL; Interventions: Drug: Long-acting somatostatin | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline solution | Intervention Type: DRUG; Name: Long-acting somatostatin; Assigned to Arm(s): somatostatin | Intervention Type: OTHER; Name: Saline solution; Assigned to Arm(s): Saline solution

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Study of the Effect of Intravenous Mircera on Hemoglobin Levels in Anemic Patients With Chronic Kidney Disease Who Are on Dialysis, and Who Have Previously Received Epoetin Alfa or Beta or Darbepoetin Alfa Treatment.
Brief Summary: This single arm study will assess the efficacy and safety of intravenous Mircera, administered with pre-filled syringes, for the treatment of anemia in patients with chronic kidney disease who are on dialysis, and who have previously received treatment with epoetin alfa or beta or darbepoetin alfa. Patients will receive monthly intravenous injections of Mircera, with the starting dose derived from the dose of epoetin alfa or beta or darbepoetin they were receiving in the week preceding study start. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
B: Arm Label: C.E.R.A; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): C.E.R.A
C: Arm Label: C.E.R.A.; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): C.E.R.A.
D: Arm Label: C.E.R.A. 120, 200, or 360 mcg; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): C.E.R.A. 120, 200, or 360 mcg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants
Brief Summary: The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age.

This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.


Options:
A: Arm Label: Darbepoetin alfa injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa Injection | Arm Label: erythropoietin alfa injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: erythropoietin alfa injection | Arm Label: placebo/control; Type: PLACEBO_COMPARATOR; Interventions: Drug: sham injection | Intervention Type: DRUG; Name: Darbepoetin Alfa Injection; Assigned to Arm(s): Darbepoetin alfa injection | Intervention Type: DRUG; Name: erythropoietin alfa injection; Assigned to Arm(s): erythropoietin alfa injection | Intervention Type: DRUG; Name: sham injection; Assigned to Arm(s): placebo/control
B: Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A
C: Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: rh G-CSF | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: rh EPO | Arm Label: G-CSF and EPO; Type: EXPERIMENTAL; Interventions: Drug: recombinant human G-CSF, and rhEPO, Drug: rh G-GSF and rh EPO together | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: recombinant human G-CSF, and rhEPO; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: rh G-CSF; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: rh EPO; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: rh G-GSF and rh EPO together; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Recombinant human Erythropoietin | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: Recombinant human Erythropoietin; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants
Brief Summary: The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age.

This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.


Options:
A: Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: rh G-CSF | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: rh EPO | Arm Label: G-CSF and EPO; Type: EXPERIMENTAL; Interventions: Drug: recombinant human G-CSF, and rhEPO, Drug: rh G-GSF and rh EPO together | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: recombinant human G-CSF, and rhEPO; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: rh G-CSF; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: rh EPO; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: rh G-GSF and rh EPO together; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A
C: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Recombinant human Erythropoietin | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: Recombinant human Erythropoietin; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
D: Arm Label: Darbepoetin alfa injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa Injection | Arm Label: erythropoietin alfa injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: erythropoietin alfa injection | Arm Label: placebo/control; Type: PLACEBO_COMPARATOR; Interventions: Drug: sham injection | Intervention Type: DRUG; Name: Darbepoetin Alfa Injection; Assigned to Arm(s): Darbepoetin alfa injection | Intervention Type: DRUG; Name: erythropoietin alfa injection; Assigned to Arm(s): erythropoietin alfa injection | Intervention Type: DRUG; Name: sham injection; Assigned to Arm(s): placebo/control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis.
Brief Summary: The purpose of this study is to investigate whether mycophenolate mofetil is effective as treatment for new cases of ANCA associated vasculitis.


Options:
A: Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Prednisone (and methylprednisolone); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: corticosteroid and azathioprine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: corticosteroid and placebo | Intervention Type: DRUG; Name: corticosteroid and azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: corticosteroid and placebo; Assigned to Arm(s): 2
C: Arm Label: mycophenolate mofetil; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate mofetil | Arm Label: cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): cyclophosphamide
D: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab plus cyclophosphamide placebo (rituximab group), Drug: Methylprednisolone (or other glucocorticoid), Drug: Prednisone | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide plus rituximab placebo (control group), Drug: Azathioprine, Drug: Methylprednisolone (or other glucocorticoid), Drug: Prednisone | Intervention Type: DRUG; Name: Rituximab plus cyclophosphamide placebo (rituximab group); Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide plus rituximab placebo (control group); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Methylprednisolone (or other glucocorticoid); Assigned to Arm(s): Control Group, Rituximab | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Control Group, Rituximab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Brief Summary: This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and whether the application of 5 mg/day everolimus as monotherapy is safe and well tolerated.


Options:
A: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
B: Arm Label: Study A, Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan, Other: Standard Blood Pressure Control | Arm Label: Study A, Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan, Other: Low Blood Pressure Control | Arm Label: Study A, Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo, Other: Standard Blood Pressure Control | Arm Label: Study A, Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo, Other: Low Blood Pressure Control | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 2, Study A, Arm 3, Study A, Arm 4 | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study A, Arm 3, Study A, Arm 4 | Intervention Type: OTHER; Name: Standard Blood Pressure Control; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 3 | Intervention Type: OTHER; Name: Low Blood Pressure Control; Assigned to Arm(s): Study A, Arm 2, Study A, Arm 4
C: Arm Label: somatostatin; Type: EXPERIMENTAL; Interventions: Drug: Long-acting somatostatin | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline solution | Intervention Type: DRUG; Name: Long-acting somatostatin; Assigned to Arm(s): somatostatin | Intervention Type: OTHER; Name: Saline solution; Assigned to Arm(s): Saline solution
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Standard; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.
Brief Summary: The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 2400mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 2400mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 2400mg/day; Assigned to Arm(s): GEn 2400mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: gabapentin | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: Inert placebo | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Inert placebo; Assigned to Arm(s): 2
C: Arm Label: Placebo (0mg/day); Type: PLACEBO_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin Low (1mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin Medium (6mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin High (30mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Intervention Type: DRUG; Name: Intraspinal Gabapentin; Assigned to Arm(s): Gabapentin High (30mg/day), Gabapentin Low (1mg/day), Gabapentin Medium (6mg/day), Placebo (0mg/day)
D: Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.
Brief Summary: The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.


Options:
A: Arm Label: Sham-laser acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham-laser acupuncture | Arm Label: gabapentine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gabapentine | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture | Intervention Type: DEVICE; Name: Sham-laser acupuncture; Assigned to Arm(s): Sham-laser acupuncture | Intervention Type: DRUG; Name: gabapentine; Assigned to Arm(s): gabapentine | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture
B: Arm Label: Placebo (0mg/day); Type: PLACEBO_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin Low (1mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin Medium (6mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Arm Label: Gabapentin High (30mg/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraspinal Gabapentin | Intervention Type: DRUG; Name: Intraspinal Gabapentin; Assigned to Arm(s): Gabapentin High (30mg/day), Gabapentin Low (1mg/day), Gabapentin Medium (6mg/day), Placebo (0mg/day)
C: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Gabapentin + Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Drug: gabapentin | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine, Gabapentin + Duloxetine | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): Gabapentin + Duloxetine
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: OTHER; Interventions: Drug: Pregabalin | Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 2400mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 2400mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 2400mg/day; Assigned to Arm(s): GEn 2400mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 36-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Including a 2 Year Extension Study to Evaluate Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-acute Myocardial Infarction Patients When Added to Optimized Standard Therapy
Brief Summary: The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
D: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Explorative, Open-Label, Multicenter, Randomized, Parallel-Group Comparative Study of Safety, Tolerability, and the Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension Over 2 Years
Brief Summary: The purpose of this study is to determine whether the study drug is effective in the long-term treatment of primary or secondary pulmonary hypertension


Options:
A: Arm Label: ACT-293987 (NS-304) and matching placebo; Type: EXPERIMENTAL; Interventions: Device: ACT-293987 (NS-304) | Intervention Type: DEVICE; Name: ACT-293987 (NS-304); Assigned to Arm(s): ACT-293987 (NS-304) and matching placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Ventavis (Iloprost, BAYQ6256) | Intervention Type: DRUG; Name: Ventavis (Iloprost, BAYQ6256); Assigned to Arm(s): Arm 1
C: Arm Label: UT-15C (oral treprositnil); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) Sustained Release Tablets; Assigned to Arm(s): UT-15C (oral treprositnil) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) sustained release tablets | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) sustained release tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: B